Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomarker Predicts Chemo Response for Osteosarcoma

Published: Wednesday, July 04, 2012
Last Updated: Wednesday, July 04, 2012
Bookmark and Share
Scientists have found that a protein expressed by some cancers is a good predictor of how the cancer will respond to standard chemotherapy.

Knowing whether a patient's tumor has this protein biomarker could help doctors determine if a patient should undergo standard treatment or if a more aggressive or alternative therapy may be more effective.

"This is the first time that a biomarker has been identified that predicts treatment success for osteosarcoma," said Dariusz Borys, assistant professor in the UC Davis Department of Pathology and Laboratory Medicine and lead author of the study. "It is a first step in individualizing therapy to maximize success based on a protein that the cancer expresses."

Osteosarcoma is usually diagnosed during the teenage years. It also may affect people over 60.

Osteosarcoma is typically treated with "neoadjuvant therapy," which involves several cycles of chemotherapy using a combination of drugs to shrink the tumor before it is surgically removed. How effective the chemotherapy is in inducing cancer cell death (necrosis) is the best predictor of a patient's survival following surgery. But a tumor's response to chemotherapy varies widely among patients and, until now, a way to predict whether the chemotherapy will work well has not been identified.

The investigators focused on a protein expressed by cancer cells known as P16, which inhibits cell growth. For unknown reasons, some cancers stop expressing P16. The researchers found that patients who had cancers that still expressed P16 were more likely to respond well to chemotherapy.
"It is useful to know ahead of time if patients are likely to respond to standard therapy," said Borys. "Those who have tumors that do not express P16 would be especially good candidates for more aggressive or experimental treatments to see if they might respond better."

The study enrolled 40 patients, aged 9 to 75 years old (median age, 15 years), with osteosarcoma at UC Davis and UC San Francisco. Pathologic specimens of the tumors before treatment were collected for study from each patient and were analyzed for P16 expression. After chemotherapy, during surgery to remove the tumor, specimens were again collected and analyzed for the extent of tumor cell death. A little more than half of the patients responded well to chemotherapy, and these patients were found to be significantly more likely to have had tumors that expressed the P16 protein.

Data on how the patients fared clinically were not available for this study, but it has been well established from other studies that the amount of tumor killed preoperatively is strongly associated with survival.

Borys said more patients will be studied to strengthen the findings, and on a molecular level, more study is needed to clarify why some cancer cells stop expressing P16.

The study was a collaboration among three institutions on the West Coast (UC Davis, UC San Francisco and University of Washington) and involved pathologists and surgeons. According to Borys, pathologists traditionally have been used to help establish a diagnosis, but are now moving toward an equally important role in helping clinicians determine treatment strategies.

"Pathologists will one day be able to provide answers to better help clinicians cure their patients," said Borys. "Our work to improve the treatment of osteosarcoma is an important step in that direction."
The article is titled, "P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy."

Other UC Davis study authors were Robert J. Canter and Steve R. Martinez, surgical oncologists at the Comprehensive Cancer Center, Robert M. Tamurian of the Department of Orthopedic Surgery, John Bishop of the Department of Pathology and Laboratory Medicine and Brian Murphy of the Veterinary School's Department of Pathology. Andrew Horvai of the UC San Francisco Medical Center was co-principal investigator with Borys. Benjamin Hoch of the University of Washington was another study author.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Tuesday, July 28, 2015
Growing Spinal Disc Tissue
Scientists develop new method for growing spinal disc tissue in the lab for combating chronic back pain.
Friday, July 03, 2015
Grant Supports Creation of Patient-Derived Stem Cell Lines
Researchers have received a two-year, $600,000 grant from the National Institute on Aging to develop and study patient-derived stem cell lines.
Thursday, December 12, 2013
Prostate Cancer Stem Cells are a Moving Target
Researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.
Friday, December 06, 2013
Researchers Change Cell Types by Flipping a Single Switch
New findings have identified a method for changing one cell type into another in a process called forced transdifferentiation.
Friday, December 06, 2013
Understanding a Protein’s Role in Familial Alzheimer’s
Researchers have used genetic engineering of human iPSC’s to specifically and precisely parse the roles of a key mutated protein in causing familial Alzheimer's disease (AD).
Monday, November 18, 2013
Researchers Un-Junking Junk DNA
A study shines a new light on molecular tools our cells use to govern regulated gene expression.
Wednesday, November 13, 2013
$100M gift launches Sanford Stem Cell Clinical Center
T. Denny Sanford has committed $100 million to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego.
Wednesday, November 06, 2013
Grafted Limb Cells Acquire Molecular ‘Fingerprint’ of New Location
Findings further creation of regenerative therapies for humans.
Wednesday, October 30, 2013
From Mature Cells to Embryonic-Like Stem Cells
Bioengineers have shown that physical cues can replace certain chemicals when nudging mature cells back to a pluripotent stage.
Tuesday, October 22, 2013
Researchers Develop Stem Cell Therapies for Acute Lung Injury
An estimated 200,000 patients a year have acute respiratory failure in the U.S. and mortality is about 30 to 40 percent.
Monday, October 21, 2013
Single Gene Mutation Linked to Neurological Disorders
Mutation could offer insights into Alzheimer’s, Parkinson’s and Huntigton’s Diseases.
Wednesday, October 16, 2013
Gene Repair Technique Could Have Many Applications
Using human pluripotent stem cells and DNA-cutting protein from meningitis bacteria, researchers have created an efficient way to target and repair defective genes.
Tuesday, August 13, 2013
Therapy Could Treat Breast Cancer that's Spread to Brain
Researchers have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
Tuesday, August 06, 2013
Scientists Streamline Production of Stem Cells
Researchers report a simple, easily reproducible RNA-based method of generating human induced pluripotent stem cells (iPSCs).
Friday, August 02, 2013
Scientific News
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Stem Cells Rescue Patients from Mitochondrial Disease
A study led by OHSU researchers has revealed a critical first step in developing a new gene and stem cell regenerative technique for treating patients with mitochondrial disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!